Drug Profile
LEO 27847
Alternative Names: LEO27847Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator LEO Pharma
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Kidney disorders; Secondary hyperparathyroidism
Most Recent Events
- 05 Apr 2016 Discontinued - Phase-I for Kidney disorders (In volunteers) in Canada (PO, liquid)
- 05 Apr 2016 Discontinued - Phase-I for Kidney disorders (In volunteers) in United Kingdom (PO, liquid and tablet)
- 05 Apr 2016 Discontinued - Phase-I for Secondary hyperparathyroidism in Germany and Poland (PO)